NewsRoom Articles

TuesdayJan 20, 2026 10:00 am

Study Discovers Molecule of Gut Bacteria That Boosts Immunotherapy Response

Scientists have identified a compound produced by gut bacteria that sharply improves how tumors respond to immunotherapy, offering a potential breakthrough for patients who currently see little benefit from these treatments. The discovery centers on a small molecule called Bac429, which enhanced lung cancer treatment outcomes in mice and is now being developed into a drug suitable for human trials. The research was led by a team at the UF Health Cancer Institute and focuses on immune checkpoint inhibitors, a class of cancer drugs designed to help the immune system recognize and attack tumors. While these therapies have changed cancer care, their effectiveness remains limited. Rachel Newsome, study author…

WednesdayJan 14, 2026 10:00 am

Cornell Researchers Develop Particles That Can Supercharge Immunotherapy

Cornell researchers have developed particles that can supercharge immunotherapy, offering a breakthrough approach to treating resistant cancers. The nanoparticles work in an unexpected dual capacity: they fundamentally alter hostile tumor conditions while amplifying the potency of existing immunotherapy drugs. Survival outcomes in mouse experiments show the efficacy of the newly developed particles. Animals with aggressive melanoma receiving the particles combined with immunotherapy drugs targeting checkpoint proteins and immune signaling molecules lived significantly longer than those getting immunotherapy drugs alone. The particles reshaped conditions inside tumors, enabling the immunotherapy drugs to mount a far more effective assault on cancer cells. The particles, designated Cornell prime dots…

WednesdayJan 14, 2026 9:45 am

Rail Vision Ltd. (NASDAQ: RVSN) Is ‘One to Watch’

Rail Vision operates in large and growing markets for railway safety, collision avoidance, and autonomous train technologies supported by favorable long-term industry trends. The company’s purpose-built rail-focused technology addresses critical safety and operational challenges, positioning it for steady growth as rail operators continue to modernize globally. A growing global footprint, including deployments, pilots, and commercial agreements across multiple regions, demonstrates early commercial traction. Ongoing investment in intellectual property, including recently granted international patents, supports defensible technology positioning. A strengthened balance sheet and continued R&D investment enhance the company’s ability to support commercialization and product development initiatives. Rail Vision (NASDAQ: RVSN) is…

WednesdayJan 14, 2026 9:00 am

ParaZero Technologies Ltd. (NASDAQ: PRZO) Announces First Successful Demonstration of the Company’s DefendAir Platform in Europe

ParaZero has successfully demonstrated the company’s DefendAir platform for the first time on European soil, following a distribution agreement that was recently signed with a leading Western European distributor Around 40 senior military officers representing several NATO member states from Western Europe attended the event where ParaZero demonstrated the full capabilities of DefendAir The live exercise showcased the platforms rapid deployment, precision targeting, interception success rate, and ability to operate well in complex environments ParaZero Technologies (NASDAQ: PRZO), an aerospace defense company, recently completed the company’s first live DefendAir demonstration on European soil. The successful demonstration followed a recently signed…

MondayJan 12, 2026 10:00 am

Health IT Firms Call for Clearer, More Consistent AI Rules

Health IT firms in the U.S. are calling for clearer, more consistent AI rules as conflicting state regulations create mounting challenges for companies operating across multiple jurisdictions. Industry leaders say the fragmented approach to AI regulation threatens to slow innovation while producing unequal care standards for patients depending on their location. President Donald Trump's administration addressed these concerns with a December 11 executive order titled Ensuring A National Policy Framework For Artificial Intelligence. The directive seeks to establish unified nationwide standards rather than permitting individual states to continue developing their own methods for regulating the rapidly evolving technology. The order directs Attorney General Pam Bondi to establish an AI Litigation Task Force to address state laws deemed to be at odds with national policy. Commerce Secretary Howard Lutnick must review existing state AI legislation and…

FridayJan 09, 2026 9:00 am

GridAI Technologies Corp. (NASDAQ: GRDX) Is ‘One to Watch’

GridAI Technologies provides exposure to the convergence of artificial intelligence, energy infrastructure modernization, and large-scale electrification trends. The Grid AI platform is software-first and hardware-agnostic, supporting scalable deployment without requiring extensive new physical infrastructure. Rising power demands from AI data centers and electrified systems create structural demand for real-time energy-orchestration solutions. The company’s legacy biopharmaceutical assets provide additional optionality alongside its expanded activities in AI-driven energy infrastructure. Public-market access through its Nasdaq listing supports capital formation, visibility, and potential strategic partnerships as deployments scale. GridAI Technologies (NASDAQ: GRDX) is a company operating at the intersection of artificial intelligence and energy infrastructure following…

ThursdayJan 08, 2026 12:00 am

ParaZero Technologies Ltd. (NASDAQ: PRZO) Is ‘One to Watch’

ParaZero operates as a defense aerospace company specializing in multi-layered Counter-UAS solutions for modern battlefield and homeland security environments. The DefendAir platform offers three complementary interception layers (airborne, turret-based, and hand-held) providing forces with flexible, low-collateral responses to diverse hostile drone threats. Company-reported demonstrations with Israeli defense authorities have shown effective real-time interception across fast, maneuverable, and RF-denied drone scenarios. DropAir delivers validated precision-delivery capability for medical and tactical supplies, including successful collaboration with the Israeli Ministry of Defense and the IDF Medical Corps. Rising global demand for cost-effective and scalable Counter-UAS systems positions ParaZero for continued expansion across defense…

WednesdayJan 07, 2026 9:00 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Is ‘One to Watch’

LIXTE is advancing a first-in-class PP2A inhibitor platform designed to enhance, rather than replace, established chemotherapy and immunotherapy regimens. The company is conducting multiple active clinical trials in solid tumors with significant unmet medical need, supported by academic and industry collaborations. LIXTE’s scientific strategy is protected by a comprehensive patent portfolio, with management noting no known direct competitors targeting PP2A inhibition. Strategic actions in 2025, including the acquisition of Liora Technologies and a registered direct offering completed in December 2025, reflect an effort to broaden capabilities and strengthen operational flexibility. Expansion of the ovarian clear cell carcinoma trial in December…

WednesdayJan 07, 2026 9:00 am

Preclinical Study Suggests Combo Therapy Could Treat Glioblastoma

University of North Carolina researchers have developed a combination treatment that shows remarkable promise against glioblastoma, an aggressive brain cancer with dismal survival rates. The therapy paired a standard chemotherapy drug with a laboratory chemical called EdU to produce unprecedented results in preclinical models. Nobel Prize winner Aziz Sancar led the research and the findings were published in the journal Proceedings of the National Academy of Sciences. His team tested EdU alongside temozolomide, known as TMZ, across multiple glioblastoma models. The concept is straightforward: combining these two compounds can destroy tumors and prevent death, Sancar explained. Together, the drugs demonstrated…

WednesdayDec 31, 2025 9:00 am

New Gene Regulator Could Revive Immune System Response in Cancer Management

A gene regulator best known for its role in bone development is now emerging as a potential lever to restore immune responses in cancer patients who stop benefiting from immunotherapy. New findings from Taiwan suggest that blocking this regulator, RUNX2, may help worn-down immune cells regain their ability to fight tumors. National Taiwan University and National Taiwan University Hospital researchers identified RUNX2 as a key factor behind immune exhaustion in liver cancer. Their work points to RUNX2 as a driver of why immune checkpoint inhibitors, once effective, can lose their impact over time. Immune checkpoint inhibitors are designed to unleash…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000